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on the measurement and reporting of clinical outcomes. CONCLUSIONS: PAS were 
pioneered by the beta interferon outcomes-based scheme for multiple sclerosis, 2002. 
Since then, published UK-based schemes favour price or volume-based schemes, a 
trend illustrated by two of the three newest schemes published in 2010. The simplicity 
of ﬁ nancial-based agreements, combined with poor health care system uptake of 
outcomes-based schemes and the demand for value-based pricing, suggests that this 
trend is set to continue.
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OBJECTIVES: Although patient access schemes (PAS) have historically been imple-
mented for high-cost oncology drugs, recent schemes for chronic diseases like rheu-
matoid arthritis (RA) have been seen in the UK. This study tries to understand how 
the shift in PAS from being accepted by payers only for short-term oncology drugs to 
those for chronic diseases like RA in the UK will inﬂ uence the situation in Italy, where 
PAS are known to be widespread. METHODS: This study used qualitative telephone 
interviews to analyze trends in the UK (n = 7) and Italy (n = 7). Interviews were 
conducted in tertiary hospitals as well as local, regional and national level reimburse-
ment authorities involving ﬁ nancial and clinical stakeholders, and key individuals in 
the implementation of the scheme. Importance of a number of variables affecting new 
PAS was ranked. RESULTS: Budget-holders in both markets were seen to be sceptical 
about the impact on long-term budgets due to the move towards PAS for chronic 
conditions. Of the 14 stakeholders interviewed, 9 said that such schemes in chronic 
conditions might help companies access markets with lesser clinical evidence on the 
basis of the class-effect of the drugs and the risk-sharing nature of the schemes. Moni-
toring of the outcomes on implementation was thought to be crucial. CONCLU-
SIONS: In Italy, increase in PAS for chronic diseases will help drug companies bring 
drugs to the market earlier. On the other hand, the payers will see this as an increased 
burden on their budgets as it will mean funding longer term treatment. Also, due to 
recent issues with monitoring of outcomes in PAS in the UK, their future needs re-
consideration. This move of PAS towards chronic conditions is expected to increase 
the impact that post-marketing monitoring will have on market access for expensive 
‘me-too’ drugs in the EU.
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OBJECTIVES: To explore major stakeholders’ incentives and disincentives to adopt 
a ﬁ nancial risk-sharing mechanism regarding budget-impact estimates of adopting new 
technologies in the Israeli National List of Health Services (NLHS). According to the 
proposed scheme, HMOs will be partially compensated by the pharmaceutical and 
medical device industry if actual use of a technology is substantially higher than what 
was projected and allocated. On the other hand, HMOs will partially refund the 
government for budgets allocated to speciﬁ c technologies that were not fully used. 
These unused budgets will be used for adopting other technologies in subsequent years. 
METHODS: Using a semi-structured protocol, we interviewed major stakeholders 
involved in the process of updating the NLHS (N = 31). Interviewees included govern-
ment ofﬁ cials, senior managers in the country’s four HMOs, pharmaceutical industry 
executives, and health economists. We inquired into the interviewee’s view towards 
our proposed risk-sharing mechanism, and their opinion on the other stakeholders’ 
incentives to accept or object the proposed scheme. RESULTS: Our interviews revealed 
a wide range of incentives, disincentives, and barriers for adopting the risk-sharing 
mechanism. There was no consensus on what would be the different stakeholders’ 
incentives and disincentives for adopting the proposed mechanism, even within the 
various stakeholders groups themselves. Most interviewees from the HMOs and the 
pharmaceutical industry supported the proposed risk-sharing agreement. Among gov-
ernment ofﬁ cials, the Ministry of Finance decision-makers tended to object to the 
proposed mechanism, while Ministry of Health executives usually supported the 
scheme, but believed that the pharmaceutical industry will not support this risk-
sharing agreement. CONCLUSIONS: Since the success of implementing a risk-sharing 
mechanism depends mainly on its perception as a win-win situation for all stakehold-
ers, we recommend that decision-makers consider the different incentives and disincen-
tives exposed in our interviews, when implementing such a mechanism. 
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OBJECTIVES: Growing attention is currently given to preventive health care. Preven-
tion can decline the appearance of several diseases and as a consequence lead to a 
decrease of health care expenses. The aim of this study was to evaluate if municipalities 
in Belgium currently are using intervention strategies for optimizing the health behav-
ior of citizens. Special attention was given to what extent certain high-risk groups are 
reached. METHODS: The design consisted of a retrospective observational design. 
The general services or—if existing—the sports services of 570 Belgian cities (308 in 
the Flanders and 262 in the Walloon region) were invited by e-mail to participate in 
the study. After the ﬁ rst mailing, another two mailings were performed. The data were 
collected using an online questionnaire with closed questions. PASW Statistics 18 was 
used for statistical analysis. RESULTS: The response rate in the Flemish region and 
Walloon region was respectively 57.47% and 16.41%. In Flanders, 94.9% of respon-
dents reported that they organize health promotion initiatives, while in Wallonia this 
percentage was 65.1%. Most common organized initiatives in the Flanders region 
were sport (74.4%) and social welfare (46.4%) initiatives. In Wallonia most common 
initiatives were prevention of disease/vaccination (45.3%) and sport (44%). Both in 
Flanders and Wallonia, initiatives concerning mental health were little organized. In 
general, the initiatives aimed at certain high-risk groups such as persons with mental 
health problems, older and disabled persons were scarce. On the level of municipal 
policy lack of appropriate ﬁ nancing was reported as the most common barrier for not 
organizing preventive strategies. CONCLUSIONS: On the level of municipal policy 
reinforcement of the value of preventive strategies concerning health promotion with 
appropriate ﬁ nancing is required. When organizing preventive initiatives, special atten-
tion to reach certain high-risk groups will be needed.
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OBJECTIVES: The issue of the introduction of co-payments is a great policy challenge 
in most of the Central-Eastern European countries. This is also the case in Hungary, 
where visit fee was introduced for health care services in 2007, and abolished one year 
later as a result of a referendum. The aim of our study is to identify different types 
of attitudes towards patient payments, and answer why visit fee was so unpopular 
among Hungarian population. METHODS: 8 focus-group discussions with health 
care consumers and physicians and 7 in-depth interviews with policy makers were 
conducted in Hungary during the summer 2009 on the attitude of patient payments 
in health care. RESULTS: Based on the transcripts and questionnaires ﬁ lled in by all 
respondents during the focus group discussions and interviews three different groups of 
attitude were identiﬁ ed. The group of “Supporters” support the introduction of patient 
payments with the aim of controlling the unnecessary use of services. The group of 
“Undecided” concern patient payments as an opportunity to provide additional resource 
for health care system by paying for “extra-better-quality services”. “Sceptics” strongly 
refuse the idea of patient payments mainly referring to ethical issues. Consumers mainly 
belong to the group of “Undecided”, while one part of the physicians belongs to “Sup-
porters”, the other part to “Sceptics”. Policy makers are all belong to the group of 
“Supporters”. CONCLUSIONS: Before the implementation of patient payments, 
mapping of population’s attitude is inevitable. In Hungary the failure of the introduc-
tion of visit fee can be explained by different expectations of health care consumers. 
They are not against to pay for health care services, but expecting better quality of 
provided services in return.
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OBJECTIVES: In the current economic climate health authorities are ﬁ nding ways to 
control spending. a popular measure is the introduction of cost containment strategies 
for pharmaceuticals to lessen the burden of cost of drugs. The objective of this research 
was to analyze the importance of different cost containment measures that payers use 
in selected markets. The research extends to analyze the gaps between the policies on 
paper and the extent these are interpreted and executed in practice. METHODS: 
Interviews were conducted with payers at the national, regional and local level in 
selected European and non-European markets. RESULTS: All countries utilise differ-
ent measures to control spending on pharmaceuticals. The measures that are used by 
markets include: internal therapeutic referencing, international price referencing, 
generic substitution, risk-sharing agreements, budget caps, proﬁ t caps, index pricing, 
price cuts, rebates and price volume agreements. The critical ﬁ nding from the research 
was that although combinations of measures are included in the national and regional 
policies, in reality their interpretation and execution varies substantially. For example, 
Spain uses internal referencing and price referencing at the national level, regions apply 
price discounts and rebates. Similarly, in the The Netherlands a preferred drug policy 
is introduced, which means that health insurers can now choose a preferred drug for 
reimbursement, which is usually the cheapest option of the reference basket. If the 
patient does not want this product, they have to pay the full price of the other product. 
Another European country which has become the recent focus is Germany; where 
price regulation will become dominant in the near future. There are uncertainties on 
achievable prices of drugs, one reason being there is lack of sophisticated systems in 
place that can monitor these measures. CONCLUSIONS: There are currently many 
developments in the area of cost containment of pharmaceuticals which will have a 
profound effect on the pharmaceutical industry.
